Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00506610
Status:
WITHDRAWN
Last Update Posted:
2012-06-07
First Post:
2007-07-24
Brief Title:
A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Flexible Escalating -Dose Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia
Status:
WITHDRAWN
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether T-62 is effective in providing relief of pain that can occur after an individual experiences a shingles outbreak which is an infection in adults caused by the same virus that causes chicken pox
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None